Where Will Eli Lilly Stock Be in 10 Years?
Source: Motley Fool
2026-03-07 11:35:00 ET
Eli Lilly (NYSE: LLY) wasn't the first to market with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs have proven more effective than competing products. That's moved Eli Lilly to the head of the pack, but investors may be a bit too excited about the company's prospects. In 10 years, the story around this stock is likely to be very different.
Sales of Mounjaro rose 99% in 2025. Zepbound's sales rose an even more impressive 175%. Eli Lilly is the clear leader in the GLP-1 drug space with these highly successful drugs.
Image source: Getty Images.
Eli Lilly and Company
NASDAQ: LLY
LLY Trading
0.45% G/L:
$1005.65 Last:
627,424 Volume:
$1006 Open:
LLY Latest News
LLY Stock Data
$977,526,804,738
935,929,919
9.81%
2658
N/A
Pharmaceuticals
Healthcare
US
Indianapolis
